[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.161.30. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Editorial
September 2008

Bridging Anticoagulation After Cardioembolic Stroke

Arch Neurol. 2008;65(9):1157. doi:10.1001/archneur.65.9.1157

Long-term anticoagulation with warfarin is accepted as an effective means of stroke prevention in patients with ischemic stroke due to a high-risk cardiac embolic source, such as cardiac thrombus, prosthetic heart valves, and many patients with atrial fibrillation. The acute management of these patients in terms of the timing and manner of anticoagulation after presentation with cardioembolic stroke is not as clear.

Proponents of early anticoagulation point to the risk of early recurrent stroke from repeat embolization. In the 1980s, the risk of recurrent embolism was felt to be as high as 10% to 20% within the first 2 weeks after ischemic stroke.1 The Cerebral Embolism Study Group2 reported a randomized trial of immediate anticoagulation with intravenous heparin within 48 hours of stroke onset vs no anticoagulation. (Antiplatelet agents were not allowed in the study.) The study was ended prematurely after only 45 patients because of recurrent stroke in 10% of the no-anticoagulation group and 0% in the heparin group.

First Page Preview View Large
First page PDF preview
First page PDF preview
×